Crinetics stock rating reiterated by Oppenheimer following Palsonify approval

Investing.comFriday, September 26, 2025 at 10:51:02 AM
Crinetics stock rating reiterated by Oppenheimer following Palsonify approval
Crinetics Pharmaceuticals has received a positive stock rating from Oppenheimer following the approval of its drug Palsonify. This endorsement is significant as it reflects confidence in the company's growth potential and the efficacy of its new treatment, which could address unmet medical needs. Investors may see this as a promising sign for future performance.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Crinetics stock price target raised to $77 from $65 at Morgan Stanley
PositiveFinancial Markets
Crinetics Pharmaceuticals has received a positive boost as Morgan Stanley raised its stock price target from $65 to $77. This increase reflects confidence in the company's growth potential and market performance, which is significant for investors looking for promising opportunities in the biotech sector.
Crinetics stock price target raised to $85 from $65 at Jones Trading
PositiveFinancial Markets
Crinetics Pharmaceuticals has received a significant boost in its stock price target, now set at $85, up from $65, according to Jones Trading. This increase reflects growing confidence in the company's potential and could attract more investors, signaling a positive outlook for Crinetics in the competitive pharmaceutical market.
Baird raises Crinetics stock price target to $62 on Palsonify approval
PositiveFinancial Markets
Baird has raised its price target for Crinetics' stock to $62 following the approval of Palsonify, a significant development for the company. This increase reflects confidence in Crinetics' future growth and the potential impact of Palsonify in the market. Investors are likely to view this news positively, as it suggests a promising trajectory for the company's financial performance.
FDA approves Crinetics' once-daily oral acromegaly treatment
PositiveFinancial Markets
The FDA has approved Crinetics' new once-daily oral treatment for acromegaly, a condition caused by excess growth hormone. This approval is significant as it offers patients a more convenient and effective option for managing their symptoms, potentially improving their quality of life. With this advancement, Crinetics is set to make a positive impact in the healthcare landscape, providing hope for those affected by this rare disorder.
Plug Power stock shows operational improvements, says Oppenheimer
PositiveFinancial Markets
Plug Power's stock is gaining attention as Oppenheimer highlights operational improvements within the company. This positive outlook is significant as it suggests that Plug Power is making strides in its business operations, which could lead to increased investor confidence and potentially higher stock prices. Investors are keen on companies that show growth and efficiency, making this news particularly relevant for those tracking the renewable energy sector.
Oppenheimer cuts Acadia Pharmaceuticals stock price target after failed study
NegativeFinancial Markets
Oppenheimer has lowered its stock price target for Acadia Pharmaceuticals following the disappointing results of a recent study. This adjustment reflects concerns about the company's future prospects and highlights the challenges faced in the pharmaceutical industry, particularly in drug development. Investors are likely to be cautious as they assess the implications of this setback on Acadia's market position.
Harmony Biosciences stock price target lowered to $62 at Oppenheimer
NegativeFinancial Markets
Harmony Biosciences has faced a setback as Oppenheimer has lowered its stock price target to $62. This adjustment reflects concerns about the company's future performance and market conditions, which could impact investor confidence and the company's growth trajectory. It's important for stakeholders to monitor these developments closely, as they may influence investment decisions and the overall health of the biotech sector.
Palvella Therapeutics stock price target raised to $90 from $85 at Oppenheimer
PositiveFinancial Markets
Palvella Therapeutics has received an optimistic boost as Oppenheimer raised its stock price target from $85 to $90. This adjustment reflects growing confidence in the company's potential and could attract more investors, signaling a positive outlook for the biotech firm.
Latest from Financial Markets
Erin Burnett Net Worth 2025: CNN Salary, Career, and Family
PositiveFinancial Markets
Erin Burnett's net worth in 2025 reflects her successful career as a prominent CNN anchor and journalist. Known for her insightful reporting and engaging style, Burnett has made a significant impact in the media landscape. Her salary and financial success highlight the value of experienced journalists in today's news environment, making her a role model for aspiring reporters. This article not only sheds light on her financial achievements but also emphasizes the importance of quality journalism in informing the public.
Wolf Blitzer Net Worth 2025: CNN Salary, Career, Family and Recent News
PositiveFinancial Markets
Wolf Blitzer's net worth is projected to grow significantly by 2025, reflecting his long-standing career at CNN and his influence in the media industry. Known for his insightful reporting and engaging presence, Blitzer has become a household name, making his financial success a topic of interest. This matters because it highlights the value of experienced journalists in today's fast-paced news environment, and it showcases how media personalities can leverage their careers for financial stability.
Anderson Cooper Net Worth 2025: CNN Salary, Vanderbilt Legacy, and Family Life
PositiveFinancial Markets
Anderson Cooper's net worth in 2025 reflects his successful career at CNN and his notable Vanderbilt family legacy. As a prominent journalist, Cooper has made a significant impact in the media landscape, and his financial success is a testament to his hard work and dedication. This article not only highlights his earnings but also delves into his family life, showcasing the balance he maintains between his professional and personal commitments. Understanding Cooper's journey is inspiring for many, as it illustrates the potential for success in the competitive world of journalism.
Los Azules copper project approved for Argentina's investment incentive regime
PositiveFinancial Markets
The Los Azules copper project has received approval for Argentina's investment incentive regime, marking a significant step forward for the mining sector in the country. This approval is crucial as it not only boosts investor confidence but also promises to enhance economic growth and job creation in the region. With the global demand for copper on the rise, this project positions Argentina as a key player in the mining industry, potentially attracting further investments and development.
Tricolor Crisis Managers Locked Out After Bankruptcy
NegativeFinancial Markets
Tricolor's sudden bankruptcy filing has raised serious concerns, especially with US prosecutors investigating potential fraud allegations against the company. Just a week after these shocking claims surfaced, a team from Vervent discovered the Tricolor headquarters in chaos and was subsequently locked out. This situation highlights the growing scrutiny on corporate practices and the importance of transparency in business operations, making it a significant story for investors and consumers alike.
Electronic Arts nears roughly $50 billion deal to go private, WSJ reports
PositiveFinancial Markets
Electronic Arts is reportedly close to finalizing a deal worth around $50 billion to go private, according to the Wall Street Journal. This move could significantly reshape the gaming industry, allowing EA to focus on long-term strategies without the pressures of public market scrutiny. Such a transition may lead to innovative game development and enhanced player experiences, making it a noteworthy development for gamers and investors alike.